Skip to main content
Clinical Trials/ISRCTN11696305
ISRCTN11696305
Completed
Not Applicable

Study to compare the effects of steroid injection vs steroid injection and hydrodilatation in the treatment of adhesive capsulitis: a randomised control trial

Joint Research Office (part of the Research Support Centre) UC0 sites170 target enrollmentMay 2, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Joint Research Office (part of the Research Support Centre) UC
Enrollment
170
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 2, 2015
End Date
April 12, 2018
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Joint Research Office (part of the Research Support Centre) UC

Eligibility Criteria

Inclusion Criteria

  • 1\. Clinical diagnosis of adhesive capsulitis
  • 2\. Normal radiograph of the shoulder
  • 3\. Restriction of range of motion compared to unaffected shoulder of at least 30 degrees in 2 of three movements; forward flexion, abduction, and external rotation in neutral measured with a goniometer.
  • 4\. Able to give informed consent
  • 5\. Diabetic, thyroid or post traumatic (e.g. post dislocation) causes may be included (otherwise slower to recruit numbers).
  • 6\. Symptoms for any period of time as long as it can be recorded
  • 7\. All patients presenting with adhesive capsulitis should be considered for the trial, but it’s the clinician’s choice if they wish to offer other treatments.

Exclusion Criteria

  • 1\. Patients unable to complete questionnaires
  • 2\. Patients under 18 or over 85
  • 3\. Any surgical intervention for adhesive capsulitis already performed
  • 4\. Pre\-existing major trauma or surgery to the shoulder
  • 5\. Patients with known or suspected musculoskeletal infection in affected shoulder
  • 6\. Patients with known or suspected malignancy
  • 7\. Steroid injection to affected shoulder less than six weeks at time of proposed intervention
  • 8\. Patient on oral steroids
  • 9\. Azathioprin, other DMD disease modifying drugs and medication taken after the intervention, in the periods of 6 weeks and 3 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials